文献速递临床试验与 GCP流行病学与生物统计

80岁及以上亚临床甲状腺功能减退症成人中左甲状腺素治疗与甲状腺相关症状的关联

Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism.
PubMed 文献 · JAMA · 2019-01-01

该研究为两项临床试验的前瞻性计划合并分析,纳入251例80岁及以上亚临床甲状腺功能减退症社区居住成人,随机接受左甲状腺素(n=112)或安慰剂(n=139)。治疗1年后,左甲状腺素组与安慰剂组在甲状腺功能减退症状评分和疲倦评分上均无显著差异;结论不支持下述人群常规使用左甲状腺素。

要点

  • 在80岁及以上亚临床甲状腺功能减退症成人中,左甲状腺素治疗1年未显著改善甲状腺功能减退症状或疲倦。
  • 左甲状腺素组与安慰剂组在12个月时的甲状腺功能减退症状评分和疲倦评分差异均无统计学显著性。
  • 研究结论不支持在80岁及以上亚临床甲状腺功能减退症成人中常规使用左甲状腺素。

核心结论

  • 在80岁及以上亚临床甲状腺功能减退症成人中,与安慰剂相比,左甲状腺素治疗与甲状腺功能减退症状或疲倦的改善无显著关联。
  • 这些发现不支持在80岁及以上亚临床甲状腺功能减退症成人中常规使用左甲状腺素治疗。

研究设计与样本

  • 前瞻性计划的两项临床试验数据合并分析,纳入社区居住的80岁及以上亚临床甲状腺功能减退症成人。
  • 第一项随机临床试验数据与第二项临床试验中80岁及以上参与者亚组相结合。
  • 两项试验于2013年4月至2018年5月进行,最终随访日期为2018年5月4日。
  • 参与者随机接受左甲状腺素(n=112;第一项试验52例,第二项试验60例)或安慰剂(n=139;第一项试验53例,第二项试验86例)。

主要发现

  • 共251例参与者(平均年龄85岁;女性118例[47%]),其中第一项临床试验105例,第二项临床试验146例;212例(84%)完成研究。
  • 甲状腺功能减退症状评分:左甲状腺素组从基线21.7降至12个月时19.3,安慰剂组从基线19.8降至12个月时17.4;校正组间差异为1.3(95%CI,-2.7至5.2;P=0.53)。
  • 疲倦评分:左甲状腺素组从基线25.5升至12个月时28.2,安慰剂组从基线25.1升至12个月时28.7;校正组间差异为-0.1(95%CI,-4.5至4.3;P=0.96)。
  • 至少发生1次不良事件:左甲状腺素组33例(29.5%),最常见不良事件为脑血管意外,发生于3例(2.2%);安慰剂组40例(28.8%),最常见不良事件为肺炎,发生于4例(3.6%)。

关键数值与推荐

  • 共同主要结局为1年时甲状腺相关生活质量患者报告结局(ThyPRO)问卷中甲状腺功能减退症状和疲倦两个领域的评分(范围0-100,评分越高生活质量越差;最小临床重要差异为9)。

临床怎么用

  • 原文结论指出,这些发现不支持在80岁及以上亚临床甲状腺功能减退症成人中常规使用左甲状腺素治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: It is unclear whether levothyroxine treatment provides clinically important benefits in adults aged 80 years and older with subclinical hypothyroidism. OBJECTIVE: To determine the association of levothyroxine treatment for subclinical hypothyroidism with thyroid-related quality of life in adults aged 80 years and older. DESIGN, SETTING, AND PARTICIPANTS: Prospectively planned combined analysis of data involving community-dwelling adults aged 80 years and older with subclinical hypothyroidism. Data from a randomized clinical trial were combined with a subgroup of participants aged 80 years and older from a second clinical trial. The trials were conducted between April 2013 and May 2018. Final follow-up was May 4, 2018. EXPOSURES: Participants were randomly assigned to receive levothyroxine (n = 112; 52 participants from the first trial and 60 from the second trial) or placebo (n = 139; 53 participants from the first trial and 86 from the second trial). MAIN OUTCOMES AND MEASURES: Co-primary outcomes were Thyroid-Related Quality of Life Patient-Reported Outcome (ThyPRO) questionnaire scores for the domains of hypothyroid symptoms and tiredness at 1 year (range, 0-100; higher scores indicate worse quality of life; minimal clinically important difference, 9). RESULTS: Of 251 participants (mean age, 85 years; 118 [47%] women), 105 were included from the first clinical trial and 146 were included from the second clinical trial. A total of 212 participants (84%) completed the study. The hypothyroid symptoms score decreased from 21.7 at baseline to 19.3 at 12 months in the levothyroxine group vs from 19.8 at baseline to 17.4 at 12 months in the placebo group (adjusted between-group difference, 1.3 [95% CI, -2.7 to 5.2]; P = .53). The tiredness score increased from 25.5 at baseline to 28.2 at 12 months in the levothyroxine group vs from 25.1 at baseline to 28.7 at 12 months in the placebo group (adjusted between-group difference, -0.1 [95% CI, -4.5 to 4.3]; P = .96). At least 1 adverse event occurred in 33 participants (29.5%) in the levothyroxine group (the most common adverse event was cerebrovascular accident, which occurred in 3 participants [2.2%]) and 40 participants (28.8%) in the placebo group (the most common adverse event was pneumonia, which occurred in 4 [3.6%] participants). CONCLUSIONS AND RELEVANCE: In this prospectively planned analysis of data from 2 clinical trials involving adults aged 80 years and older with subclinical hypothyroidism, treatment with levothyroxine, compared with placebo, was not significantly associated with improvement in hypothyroid symptoms or fatigue. These findings do not support routine use of levothyroxine for treatment of subclinical hypothyroidism in adults aged 80 years and older. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01660126; Netherlands Trial Register: NTR3851.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Mooijaart SP, Du Puy RS, Stott DJ, et al. Association Between Levothyroxine Treatment and Thyroid-Related Symptoms Among Adults Aged 80 Years and Older With Subclinical Hypothyroidism. JAMA. 2019. PMID: 31664429. doi:10.1001/jama.2019.17274

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。